30-day average of 21 articles Β· scale β100 to +100
Across 21 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Novo Nordisk A/S news is Slightly Bullish (+24)
on a scale from β100 to +100.
That is up 19 points from the previous 30 days (+5).
π Novo Nordisk surpassed JPMorgan forecasts with 8M+ cumulative Wegovy prescriptions.
π Operating profit dropped 9% YoY due to planned high-volume, low-price shift.
Somewhat Bullish +45
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo ...
AI-generated analysis
Key insights
π Novo Nordisk exceeded JPMorgan analyst predictions with over eight million cumulative prescriptions for its Wegovy pill since launch.
π The company's oral GLP-1 pill has achieved even greater market success than the initial injection-based Wegovy shot.
π Operating profit fell 9% year over year as the company executes a planned strategic shift to a high-volume, low-price business model.
π° Novo Nordisk offers a 4.4% dividend yield, which is well above the pharmaceutical industry average of 1.3%.
π The stock has declined 70% from its 2024 peak, trading at price-to-sales and price-to-earnings ratios below five-year averages.
β οΈ The company faces competition from Eli Lilly's existing GLP-1 pill and other rivals waiting to enter the market with their own drugs.
π Bullish signals
πNovo Nordisk successfully launched its Wegovy pill, accumulating over eight million cumulative prescriptions since the product's introduction.
πThe company's oral GLP-1 pill has proven more successful in adoption than the initial injection-based Wegovy shot.
π°Novo Nordisk offers a 4.4% dividend yield, which is significantly higher than the pharmaceutical sector average of 1.3%.
πThe stock trades at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios.
πStrong adoption rates for the Wegovy pill indicate that the company's strategic transition to a high-volume model is progressing as planned.
π Risk factors
πOperating profit fell 9% year over year in the quarter due to the deliberate shift toward a low-price, high-volume business model.
πCurrent revenues and earnings are being depressed by the company's strategic pricing strategy during this transition period.
β οΈNovo Nordisk faces direct competition from Eli Lilly, which already has its own GLP-1 pill on the market.
Article
Novo Nordisk (NYSE: NVO) has successfully met JPMorgan analyst expectations for strong sales of its Wegovy oral pill, having accumulated over eight million cumulative prescriptions since the product's launch. The company was the first to market with a GLP-1 weight-loss shot and subsequently the first to introduce the pill format, which has proven even more successful than the injection in terms of adoption.
Despite this strong product performance, Novo Nordisk reported a 9% year-over-year decline in operating profit for the quarter. Management attributes this decline to a strategic shift toward a high-volume, low-price business model designed to maximize market penetration. While revenues and earnings are currently depressed by this pricing strategy during what the company defines as a transition year, the strong adoption rates suggest the long-term plan is progressing as intended.
The stock has fallen 70% from its 2024 peak, trading at valuations below its five-year averages for price-to-sales, price-to-earnings, and price-to-book ratios. It offers a 4.4% dividend yield, significantly higher than the pharmaceutical sector average of 1.3%, supported by a strong 33% payout ratio. While conservative investors may prefer to wait for profits to fully reflect the new model, the current risk/reward balance appears tilted toward reward for income and value-oriented investors.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Company updateFinancial outlookAI-generated analysis
Novo Nordisk's (NYSE:NVO) investment narrative has shifted significantly as the stock declined over 25% since early 2026, settling at a forward P/E of 11.83x compared to 13.33x in September 2025. This valuation compression reflects growing competitive pressures from Eli Lilly, pricing challenges in the U.S., and slower-than-anticipated momentum for its new oral semaglutide product, Wegovy.
Despite these headwinds, Novo maintains a substantial franchise with 2025 sales reaching DKK 309 billion and obesity-care sales climbing to DKK 82 billion. The company successfully launched the Wegovy pill in January 2026, surpassing three million prescriptions by June, and introduced a higher-dose 7.2 mg formulation to expand its addressable market beyond injectables.
However, Novo faces a difficult environment where first-mover advantage is no longer sufficient against Eli Lilly's strong Mounjaro and Zepbound sales. While management raised its 2026 outlook in August, the guidance still projects 0% to -6% growth at constant exchange rates, driven by GLP-1 volume rather than a return to high growth rates.
The company's future hinges on its pipeline, specifically CagriSema which showed superior weight loss results in recent trials, and ambitions to launch five multi-blockbuster medicines by 2030. Investors must determine if the current valuation represents a temporary reset or a fundamental change in Novo's growth trajectory amidst credible competition.
π Stock down >25% since early 2026 amid competitive pricing pressures.
π Oral Wegovy prescriptions surpassed three million by June 2026.
π 2025 sales hit DKK 309 billion with obesity care at DKK 82 billion.
β οΈ Faces strong Eli Lilly competition and challenging growth outlook.
𧬠CagriSema trial shows superior weight loss versus tirzepatide.
π Novo Nordisk stock declined over 25% since early 2026, trading at 11.83x forward earnings as investors price in competitive and pricing pressures.
π The company launched the oral Wegovy pill in January 2026, with total prescriptions surpassing three million by June 2026.
π Novo reported 2025 sales of DKK 309 billion with obesity-care sales reaching DKK 82 billion and continued GLP-1 volume growth.
βοΈ Eli Lilly is gaining significant ground, with Mounjaro sales jumping 91% to $9.94 billion in Q2 2026 while Novo's Wegovy pill generated $497 million.
π Management raised its 2026 adjusted sales outlook in August, but the new guidance still calls for 0% to -6% growth at constant exchange rates.
𧬠CagriSema remains a critical pipeline opportunity, showing superior weight loss to tirzepatide in the REIMAGINE 5 trial and 21% weight loss versus placebo.
π― Novo Nordisk aims to launch more than five multi-blockbuster medicines by 2030 and generate over DKK 150 billion in pipeline sales by 2035.
β οΈ The company faces credible competition, increasing pricing pressure, and a challenging outlook that prevents it from being treated as an obvious bargain.
Bullish Signals
Oral Wegovy pill launched Jan 2026; prescriptions hit 3M by June.
2025 sales DKK 309B with 17% CAGR in obesity/diabetes care.
CagriSema showed 21% weight loss vs placebo in REIMAGINE 5 trial.
Aims to launch five multi-blockbuster medicines by 2030.
Risk Factors
Lilly Mounjaro sales jumped 91% to $9.94B Q2 2026 vs Novo's $497M Wegovy pill.
Bullish Signals
Novo Nordisk launched the oral Wegovy pill in January 2026, with total prescriptions surpassing three million by June, demonstrating successful expansion into new dosage forms.
The company reported 2025 sales of DKK 309 billion with a compound annual growth rate of 17%, maintaining one of the world's largest positions in obesity and diabetes care.
CagriSema produced superior weight loss to tirzepatide in the REIMAGINE 5 trial, showing 21% weight loss versus placebo in adults with overweight or obesity.
Management aims to launch more than five multi-blockbuster medicines by 2030, providing a credible route back to growth beyond current franchises.
Risk Factors
Novo Nordisk faces stronger competition from Eli Lilly, with Lilly's Mounjaro sales jumping 91% to $9.94 billion in Q2 2026 while Novo's Wegovy pill generated only $497 million.
The company is experiencing pricing pressure in the U.S. market and slower-than-expected momentum from its new oral semaglutide product, Wegovy.
Management raised its 2026 outlook but guidance still projects 0% to -6% growth at constant exchange rates, indicating a decline in adjusted sales and operating profit.
The investment case now depends on whether current problems represent a temporary reset or a fundamental change in Novo's long-term growth trajectory.
Novo Nordisk shares rose 1.12 percent to EUR 34.41 ahead of its scheduled earnings release for the first nine months of 2026, expected on November 4. The stock's recent performance reflects investor anticipation regarding volume growth against pricing pressures and lower analyst targets.
Market sentiment has shifted negatively following BMO Capital's downgrade of its price target from USD 47.00 to USD 40.00 on October 12. Analysts noted that while the uptake of Wegovy HD injectable is underappreciated, growth in the pill form factor is already priced into expectations.
Company financial activity includes a significant share repurchase program where Novo Nordisk bought back 23.09 million B shares by October 9 for DKK 6.76 billion. This brings total purchases since February to 37.85 million shares worth DKK 10.56 billion, with treasury shares now at 1.20 percent of capital.
Recent Q2 results showed adjusted sales of DKK 78.49 billion and operating profit of DKK 33.39 billion, both up significantly year-over-year. However, the company has lowered its full-year outlook for adjusted sales and operating profit to a range of 0 percent to minus 6 percent at constant exchange rates.
Management reaffirmed its strategic goal to serve more than 60 million patients by 2030 during a September Capital Markets Day. The upcoming November earnings report will be critical in testing whether operational volume growth can successfully offset the reduced pricing environment and lower analyst guidance.
π Stock rose 1.12% to EUR 34.41 ahead of Nov 4, 2026 results.
π BMO lowered price target to USD 40 due to lower outlook levels.
π° Repurchased 23.09M shares for DKK 6.76B under program ending Feb 1, 2027.
π Q2 sales up 7% but full-year guidance cut to 0% to -6%.
π― Aims to serve over 60M patients by 2030 per Capital Markets Day.
π Novo Nordisk stock gained 1.12 percent to EUR 34.41 ahead of its first nine-month results scheduled for November 4, 2026.
π BMO Capital lowered its price target from USD 47.00 to USD 40.00 while maintaining a Market Perform rating due to lower outlook levels.
π° The company repurchased 23.09 million B shares by October 9 under a program running through February 1, 2027, totaling DKK 6.76 billion.
π Q2 adjusted sales reached DKK 78.49 billion (up 7%) and operating profit hit DKK 33.39 billion (up 11%), though full-year guidance was cut to 0% to -6%.
π Analysts suggest Wegovy HD injectable uptake is underappreciated, while growth in the oral pill form factor is already reflected in current expectations.
π― Novo Nordisk aims to serve more than 60 million patients by 2030, a target set during its September Capital Markets Day.
π Treasury shares now stand at 1.20 percent of total share capital following recent buyback transactions totaling DKK 10.56 billion since February.
β οΈ The upcoming earnings report will test if volume growth can offset pricing pressure and the lower target levels set by analysts like BMO Capital.
Bullish Signals
Repurchased 23.09M shares for DKK 6.76B.
Q2 sales grew 7% to DKK 78.49B.
Operating profit rose 11% to DKK 33.39B.
Wegovy HD uptake suggests future upside.
Committed to serving 60M patients by 2030.
Risk Factors
BMO cut price target from USD 47.00 to USD 40.00.
Outlook lowered to 0% to minus 6% at constant rates.
Investors worry volume growth offsets pricing pressure before earnings.
Bullish Signals
Novo Nordisk repurchased 23.09 million B shares for DKK 6.76 billion by October 9, reducing outstanding share count and potentially supporting per-share value.
Q2 adjusted sales grew 7% to DKK 78.49 billion and operating profit increased 11% to DKK 33.39 billion at constant exchange rates.
Analysts indicate that the uptake of Wegovy HD injectable is currently underappreciated by the market, suggesting potential upside in future performance.
The company maintains a clear strategic goal to serve more than 60 million patients by 2030, demonstrating long-term growth commitment.
Risk Factors
BMO Capital cut its price target from USD 47.00 to USD 40.00 on October 12, citing lower target levels and noting that pill growth is already priced in.
The company lowered its full-year adjusted sales and operating profit outlook to a range of 0% to minus 6% at constant exchange rates.
Investors are concerned about whether volume growth can offset ongoing pricing pressure before the November 4 earnings release.
AI partnershipDrug approvalNew drug indicationAI-generated analysis
Zacks Equity Research analysts have released a new report highlighting Novo Nordisk A/S (NVO), noting that its shares have underperformed the Large Cap Pharmaceuticals industry over the past year, dropping 29.6% compared to a 30% gain for the sector.
Despite the recent stock weakness, the company raised its 2026 outlook, though growth remains weighed down by intensifying competition, pricing pressure, and higher spending which cloud hopes for an immediate turnaround. The report emphasizes that Novo Nordisk recently rebranded as 'Novo' while continuing to drive revenue through volume gains in its semaglutide drugs for obesity and diabetes.
Key positive developments include label expansions in other indications likely to boost sales, the approval of a higher-dose Wegovy in both the EU and United States, and FDA approval for the Wegovy pill for obesity which has already surpassed five million prescriptions. Additionally, partnerships with major technology firms like OpenAI, AWS, and Anthropic are cited as positives aimed at boosting drug discovery capabilities.
The article concludes that while the stock faces headwinds from competition and margin pressures, the combination of volume growth, new indications, regulatory approvals for higher-dose formulations, and strategic AI partnerships provides a foundation for future expansion.
π Novo Nordisk shares fell 29.6% vs 30% sector gain last year.
π Rebranded as 'Novo' with strong volume growth in semaglutide drugs.
π Raised 2026 outlook despite competition and pricing pressure challenges.
β Higher-dose Wegovy approved in EU and US to expand market reach.
π€ Partnerships with OpenAI, AWS, and Anthropic enhance drug discovery capabilities.
π Novo Nordisk's shares have underperformed the Large Cap Pharmaceuticals industry over the past year, falling 29.6% versus a 30% sector gain.
π The company recently rebranded as 'Novo' while maintaining strong growth driven by volume gains in its semaglutide drugs for obesity and diabetes.
π Novo Nordisk raised its 2026 outlook despite ongoing challenges from intensifying competition, pricing pressure, and higher spending.
π Label expansions in other indications are expected to further boost sales revenue for the company.
β A higher-dose Wegovy formulation has been approved in both the EU and the United States, expanding its market reach.
π The Wegovy pill secured FDA approval for obesity treatment and has already surpassed five million prescriptions since its launch.
π Novo Nordisk's Ozempic pill has successfully launched in the U.S. market specifically for diabetes management.
π€ Strategic partnerships with OpenAI, AWS, and Anthropic are established to enhance drug discovery capabilities.
π¬ These technology collaborations represent a positive step toward accelerating innovation within the company's pipeline.
Bullish Signals
Raised 2026 outlook showing management confidence.
BMO Capital Management has lowered its price target for Novo Nordisk from USD 47.00 to USD 40.00, citing concerns regarding the uptake of the Wegovy HD injectable and lower-than-expected growth in oral medication segments. Despite this downgrade, BMO maintained a Market Perform rating, signaling that the investment case relies heavily on near-term execution capabilities rather than long-term pipeline potential. The stock was trading at EUR 34.66 on October 13, 2026, with a market capitalization of USD 171.3 billion.
Novo Nordisk reported adjusted Q2 2026 sales of DKK 78.49 billion, representing a 7% increase at constant exchange rates, while adjusted operating profit rose by 11% to DKK 33.39 billion. However, the company recorded a significant non-cash impairment charge of DKK 6.30 billion related to intangible pipeline assets. For the full year 2026, Novo Nordisk has revised its guidance for adjusted sales and operating profit growth to a range between 0% and -6%, which is an improvement from the previously expected decline of -4% to -12%.
The company outlined a strategic roadmap targeting more than five multi-blockbuster launches by 2030, with risk-adjusted pipeline sales projected to exceed DKK 150 billion by 2035. Investors will closely watch the upcoming quarterly results scheduled for November 4, 2026, which are expected to test the validity of the company's revised annual outlook and its ability to address the specific growth concerns highlighted by BMO.
π BMO lowered price target to USD 40 on Oct 12, 2026.
π Q2 adjusted sales rose 7% to DKK 78.49 billion.
π° Operating profit grew 11% to DKK 33.39 billion.
β οΈ Company recorded DKK 6.30 billion non-cash impairment charge.
π Full-year guidance revised to 0% to -6% growth.
π BMO Capital lowered its Novo Nordisk price target from USD 47.00 to USD 40.00 on October 12, 2026.
π Q2 2026 adjusted sales reached DKK 78.49 billion, up 7% at constant exchange rates.
π° Adjusted operating profit for Q2 2026 increased by 11% to DKK 33.39 billion.
β οΈ The company recorded a DKK 6.30 billion non-cash impairment charge linked to intangible pipeline assets.
π Full-year 2026 guidance for adjusted sales and operating profit growth was revised to 0% to -6%.
π¬ Novo Nordisk targets more than five multi-blockbuster launches by 2030 with over DKK 150 billion in pipeline sales by 2035.
π Analyst concerns focus on the uptake of Wegovy HD injectable and expectations for pill-based growth.
π Next quarterly results are scheduled for November 4, 2026, before market open.
π’ Novo Nordisk stock traded at EUR 34.66 with a market cap of USD 171.3 billion as of October 12.
Revised full-year 2026 guidance improved to 0% to -6% growth.
Targets five multi-blockbuster launches by 2030 with DKK 150B pipeline.
Risk Factors
BMO lowered target to $40 due to Wegovy uptake concerns.
Recorded DKK 6.3B impairment on pipeline assets in Q2 2026.
Bullish Signals
Novo Nordisk reported adjusted Q2 2026 sales growth of 7% and adjusted operating profit growth of 11%, demonstrating strong operational performance.
The company revised its full-year 2026 guidance for adjusted sales and operating profit growth to a range of 0% to -6%, which is an improvement over the prior expectation of -4% to -12%.
Novo Nordisk has set an ambitious strategy targeting more than five multi-blockbuster launches by 2030, projecting risk-adjusted pipeline sales of over DKK 150 billion by 2035.
Risk Factors
BMO Capital lowered its price target from USD 47.00 to USD 40.00 due to concerns about Wegovy HD injectable uptake and lower-than-expected pill-growth expectations.
The company recognized a DKK 6.30 billion non-recurring, non-cash impairment charge linked to intangible pipeline assets in Q2 2026.
Novo Nordisk A/S initiated a specific share repurchase programme on May 6, 2026, authorizing the buyback of B shares up to DKK 11.2 billion between May 6 and February 1, 2027. This initiative is a component of a broader, larger-scale treasury stock program approved earlier in the year.
As of October 9, 2026, Novo Nordisk has executed significant buybacks under this framework, purchasing approximately 37.85 million B shares at an average price of DKK 278.97 per share. These transactions have resulted in a total transaction value exceeding DKK 10.5 billion.
Following these acquisitions, the company holds a treasury stake of 51,889,876 B shares, representing 1.2% of its total share capital. The aggregate number of A and B shares outstanding, including treasury shares, stands at 4.465 billion.
π Novo Nordisk launched DKK 11.2B share buyback program on May 6, 2026.
π° Company spent DKK 10.5B to acquire 37.85M shares by October 9, 2026.
π Average repurchase price for B shares reached DKK 278.97 per share.
π¦ Treasury holdings now total 51.9M B shares, representing 1.2% of capital.
π Repurchase initiative covers 12 months with total cap of DKK 15 billion.
π Novo Nordisk launched a dedicated share repurchase program on May 6, 2026, targeting up to DKK 11.2 billion in B share buybacks.
π° As of October 9, 2026, the company has spent over DKK 10.5 billion to acquire approximately 37.85 million shares.
π The average purchase price for repurchased B shares was DKK 278.97 per share during the reporting period.
π¦ Novo Nordisk's current treasury holdings total 51,889,876 B shares, equivalent to 1.2% of the company's total share capital.
π The broader share repurchase initiative covers a 12-month window starting from February 4, 2026, with a total cap of DKK 15 billion.
π Novo Nordisk operates as a global healthcare leader with over 67,000 employees focused on treatments for lasting health.
Bullish Signals
Buybacks spent DKK 10.5B for 38M shares by Oct 2026.
Holds 1.2% treasury stake showing confidence in long-term value.
Bullish Signals
Novo Nordisk is actively reducing its share count through a structured buyback program, having already spent over DKK 10.5 billion to acquire nearly 38 million shares as of October 2026.
The company holds a significant treasury stake of 1.2% (approx. 51.9 million shares), demonstrating confidence in its long-term value and commitment to capital return strategies.
Novo Nordisk (NVO) trades at a low forward multiple of approximately 9.5x earnings, reflecting market concerns over structural pricing pressures and stagnant growth expectations. The company recently guided for flat operating margins through 2030 following a significant U.S. price cut to its Wegovy and Ozempic products, which has already impacted prescription volumes and sales guidance for 2026.
While Novo possesses substantial optionality in its oral obesity pipeline and late-stage candidates like amycretin, the market currently views these as unproven drivers of recovery rather than immediate earnings support. Analysts have trimmed growth estimates due to the combination of government-imposed price reductions and competition from rivals like Eli Lilly.
The investment thesis for Novo Nordisk hinges on whether the current low valuation represents a temporary trough or a long-term value trap given the company's own cautious guidance. Unlike peers with scheduled patent cliffs, Novo faces ongoing margin compression that requires successful pipeline validation to justify its discount and restore growth trajectory.
π NVO trades at 9.5x forward multiple amid flat earnings and stagnant growth expectations through 2030.
π Wegovy/Ozempic U.S. list prices dropped to $350, driving a 15% decline in prescription volumes.
π Analysts trimmed expected EPS growth from 12% to 9% for 2027-2030 due to pricing squeeze.
π° Citi forecasts Q3 sales down 4% as U.S. Ozempic volumes fall roughly 15%.
π Oral obesity pipeline shows promise internationally with peak sales estimates raised to $13 billion.
π NVO trades near $39 at a 9.5x forward multiple, reflecting market pricing of flat earnings and stagnant growth expectations through 2030.
π U.S. list prices for Wegovy and Ozempic dropped from over $1,000 to $350 due to federal retail channel agreements, driving a 15% decline in prescription volumes.
π Management has explicitly guided for operating margins to remain broadly stable through 2030 rather than expanding despite the company's dominant market position.
π° Citi estimates U.S. Ozempic prescription volumes have fallen roughly 15%, with third-quarter sales forecast down about 4% in constant currency.
π The oral obesity pipeline shows promise internationally, with peak sales estimates raised to $13 billion and strong early efficacy data for amycretin.
π Analysts have trimmed expected EPS growth from 12% to 9% for the 2027-2030 period due to the structural nature of the pricing squeeze.
βοΈ The stock is viewed as a high-risk lottery ticket with enormous upside potential contingent on pipeline success rather than a safe value play.
Bullish Signals
Oral Wegovy gained traction internationally with one million packs sold in U.K.
Amycretin showed 13% weight loss, twice Wegovy's efficacy in early trials.
CagriSema achieved 22.7% weight loss in Phase 3, validating obesity strategy.
Risk Factors
2026 sales projected to drop 5-13% due to U.S. pricing cuts.
Bullish Signals
The oral version of Wegovy is gaining traction internationally, moving about one million packs through the U.K. since July.
Pipeline candidate amycretin reported approximately 13% weight loss at 12 weeks in early trials, roughly twice the efficacy of current Wegovy.
Another pipeline drug, CagriSema, demonstrated 22.7% weight loss at 68 weeks in Phase 3 data, validating the company's long-term obesity strategy.
Risk Factors
The company guided for a 5% to 13% decline in 2026 sales driven by U.S. pricing cuts rather than lost demand.
Management has committed to keeping operating margins broadly stable through 2030, signaling an end to the high-growth era.
Citi cut its target price and estimates that the structural pricing squeeze is not cyclical but a permanent headwind.
The market is pricing in flat earnings rather than a rebound, creating skepticism about the sustainability of current growth rates.
Company updateRegulatory approvalAI-generated analysis
Novo Nordisk announced on October 2 that its hemophilia A candidate denecimig (Mim8) remains under review by the US FDA with no new decision timeline. The company attributes this extended review to ongoing remediation at a manufacturing facility, noting that the FDA has not identified deficiencies in the clinical efficacy or safety data submitted for the application.
Despite positive feedback from Europe's CHMP and research published in the New England Journal of Medicine, the US market launch is delayed until the first half of 2027, contingent on regulatory approval. The article clarifies that while the drug's molecular design effectively mimics activated factor VIII to facilitate clotting, commercial delivery depends entirely on resolving manufacturing quality requirements.
Clinical data from the FRONTIER2 study showed a 98.7% relative reduction in annualized treated-bleeding rates for patients on monthly Mim8 compared to on-demand treatment. However, the delay highlights that clinical success does not guarantee immediate market entry; Novo states the update does not affect its 2026 financial outlook but introduces uncertainty regarding the product's revenue trajectory and launch timing in the US.
The FDA emphasizes that review covers manufacturing processes and facilities to ensure identity, strength, consistency, and purity are reliably controlled. Novo confirms the facility issue is specific to this candidate and does not affect other marketed products, though the lack of a revised timetable means investors must monitor remediation progress closely before the planned H1 2027 launch.
π FDA review continues for denecimig due to manufacturing remediation until 2027 launch.
π¬ Clinical efficacy remains strong with 98.7% bleeding reduction despite US approval delay.
πͺπΊ Europe's CHMP issued positive marketing authorization opinion in September for Frehemgo.
π° Manufacturing update does not impact Novo Nordisk's overall 2026 financial outlook.
β οΈ Delay creates revenue uncertainty while FDA requires repeatable manufacturing processes.
π Novo Nordisk confirmed on October 2 that denecimig (Mim8) remains under FDA review with no new decision timeline due to ongoing manufacturing facility remediation.
π¬ The US FDA has not identified deficiencies in the clinical efficacy or safety data for Mim8, distinguishing the delay from a rejection of the drug's therapeutic value.
π Europe's CHMP issued a positive opinion in September recommending marketing authorization for denecimig under the name Frehemgo.
π Clinical results from the FRONTIER2 study demonstrated a 98.7% relative reduction in annualized treated-bleeding rates compared to on-demand treatment groups.
π The FDA requires that manufacturing processes be 'repeatable' and reliable, meaning producing one acceptable batch is insufficient for approval without robust quality controls.
π Novo Nordisk aims to launch denecimig in the US in the first half of 2027, subject to a successful regulatory decision following remediation.
π° The company stated that this specific manufacturing update does not affect its overall 2026 financial outlook or other marketed products.
π The delay introduces uncertainty regarding the product's revenue trajectory and launch timing in the US market despite strong clinical data.
𧬠Mim8 is a bispecific antibody designed to mimic activated factor VIII, facilitating clotting for patients with or without factor VIII inhibitors.
βοΈ Novo Nordisk clarified that the facility feedback does not affect its other marketed products and there is no evidence of contamination or equipment failure affecting every batch.
Bullish Signals
FDA confirmed no deficiencies in denecimig efficacy data.
Risk Factors
FDA review unfinished due to facility remediation with no timeline.
Bullish Signals
The FDA has not identified deficiencies in the clinical efficacy or safety data submitted for denecimig, confirming the drug's therapeutic potential.
Europe's CHMP issued a positive opinion in September recommending marketing authorization for denecimig (Frehemgo), validating its global development progress.
Clinical data from the FRONTIER2 study showed a 98.7% relative reduction in annualized treated-bleeding rates, demonstrating significant efficacy over on-demand treatment.
Novo Nordisk confirmed that the manufacturing remediation issue is specific to denecimig and does not affect its other marketed products or overall 2026 financial outlook.
Risk Factors
The US FDA review for denecimig remains unfinished due to ongoing remediation at a manufacturing facility, with no new decision timeline provided.
The planned US launch is delayed until the first half of 2027, creating uncertainty regarding the product's revenue trajectory and market entry timing.
FDA approval requires that manufacturing processes be 'repeatable' and reliable, meaning Novo must resolve quality control issues before commercial delivery can begin.
Citi Research has lowered its price target on Novo Nordisk (NVO) to 296 Danish crowns from 310, maintaining a neutral rating. The analysts cited the company's guidance for broadly stable margins through 2030 as the primary driver, noting that this leaves little room for future margin expansion. Consequently, Citi reduced its adjusted operating profit forecasts for the 2028-2030 period by 2% to 4%.
The downgrade reflects a shift in valuation assumptions, with Citi now expecting Novo Nordisk to trade at 14 times 2027 earnings compared to a previous expectation of 15 times. Additionally, the expected annual earnings-per-share growth rate for 2027-2030 was cut from 12% to 9% due to the lack of anticipated margin growth. Despite these headwinds, Citi raised its short-term adjusted operating profit forecasts for 2026 and 2027 by 2% to 3%, driven by higher expected sales of the Wegovy pill outside the United States.
Looking at specific product performance, Citi lifted its peak sales forecast for the Wegovy pill to $13 billion from $10 billion, citing a successful UK launch where 1 million packs have been distributed since July. The company plans to launch the Wegovy pill in at least 20 countries by the end of 2027, aiming to cover two-thirds of the obesity market it currently serves. However, analysts remain cautious about long-term threats from competitors and poor visibility on injectable Wegovy pricing.
For the upcoming third-quarter results report on Nov. 4, Citi forecasts sales of kr73.5 billion, down 4% at constant currency, despite the new pill launch. The decline is attributed to a roughly kr3 billion rebate adjustment in the year-earlier quarter, continued prescription declines for Ozempic in the U.S., and price declines for injectable Wegovy. Furthermore, Citi expects IFRS earnings per share of kr4.15, down 8% from a year earlier, primarily due to an impairment following the failure of ziltivekimab in the ZEUS trial.
π Citi cuts NVO price target to 296 DKK citing stable margin guidance through 2030.
π Analysts lower 2028-2030 adjusted operating profit forecasts by 2% to 4%.
π° Citi raises 2026-2027 profit forecasts 2% due to strong non-US Wegovy sales growth.
β οΈ IFRS EPS expected to drop 8% to kr4.15 from ziltivekimab trial impairment.
π₯ Competitor threats and pricing uncertainty may keep investors on the sidelines for NVO.
π Citi Research cut its price target on Novo Nordisk to 296 Danish crowns from 310 due to guidance for broadly stable margins through 2030.
π The analyst firm lowered adjusted operating profit forecasts for 2028-2030 by 2% to 4% and reduced expected EPS growth to 9% from 12%.
π° Citi raised its 2026 and 2027 adjusted operating profit forecasts by 2% to 3%, citing higher sales of the Wegovy pill outside the U.S.
π Novo Nordisk intends to launch the Wegovy pill in at least 20 countries by the end of 2027, covering two-thirds of its current obesity market.
π΅ Citi lifted its peak sales forecast for the Wegovy pill to $13 billion from $10 billion following a strong UK launch with 1 million packs distributed.
π Q3 sales are forecast at kr73.5 billion, down 4% at constant currency, driven by rebate adjustments and prescription declines for Ozempic in the U.S.
β οΈ IFRS earnings per share are expected to drop 8% to kr4.15 due to an impairment after the failure of ziltivekimab in the ZEUS trial.
π₯ Analysts warn that poor visibility on injectable Wegovy pricing and growing long-term threats from competitors like Eli Lilly and Pfizer may keep investors on the sidelines.
Bullish Signals
Citi raised 2026 adjusted sales forecasts by 3%.
Citi raised peak Wegovy pill forecast to $13B.
Launching Wegovy in 20 countries by end of 2027.
Risk Factors
Citi cut target due to stable margins leaving little growth room.
Bullish Signals
Citi raised its adjusted sales forecasts by 3% for 2026 and 1% for 2027, driven by higher expected sales of the Wegovy pill outside the United States.
The company plans to launch the Wegovy pill in at least 20 countries by the end of 2027, aiming to cover two-thirds of the obesity market it currently serves.
Citi lifted its peak sales forecast for the Wegovy pill to $13 billion from $10 billion following a strong UK launch where 1 million packs have been distributed since July.
Risk Factors
Citi cut its price target due to guidance for broadly stable margins through 2030, which leaves little room for future margin growth.
Adjusted operating profit forecasts for 2028-2030 were lowered by 2% to 4%, and expected annual EPS growth was cut from 12% to 9%.
Q3 sales are forecast at kr73.5 billion, down 4% at constant currency, due to a roughly kr3 billion rebate adjustment in the year-earlier quarter.
Ozempic prescriptions declined 15% in the U.S., and there are continued price declines for injectable Wegovy affecting revenue.
IFRS earnings per share are expected to fall 8% to kr4.15, mainly because of an impairment after the failure of ziltivekimab in the ZEUS trial.
Novo Nordisk released fresh real-world data supporting its metabolic franchise, including a retrospective analysis showing that patients switching from injectable to oral Wegovy lost an average of 4.1% body weight over three months via the Ro telehealth platform.
The company also published a large-scale study involving over 636,000 adults with type 2 diabetes, finding that escalating semaglutide doses was associated with a 6% lower risk of serious cardiovascular events compared to switching to tirzepatide, bolstering its competitive standing despite the study's inability to prove causation.
In its development pipeline, the FDA extended its review of denecimig, a hemophilia A candidate, due to manufacturing site corrections. Management confirmed that this delay will not impact 2026 financial guidance, with the US launch still targeted for the first half of 2027.
π Novo Nordisk saw 4.1% weight loss in patients switching to oral Wegovy.
β οΈ CFRA downgraded Novo Nordisk stock from hold to sell with a $38 price target, citing unfavorable risk-reward and mounting competitive pressure.
π The FDA extended the review of denecimig, a hemophilia A candidate, due to necessary manufacturing site corrections.
π° Management stated that the delay in denecimig will not affect 2026 financial guidance or the first-half-2027 US launch target.
π Novo Nordisk shares fell noticeably following skepticism from investors regarding management's long-term growth targets and muted earnings outlook.
Bullish Signals
Oral Wegovy users shed 4.1% body weight over three months.
Escalating semaglutide lowers CV risk by 6% vs tirzepatide.
Risk Factors
CFRA downgraded to sell with $38 target citing competitive pressure.
Investors skeptical of growth targets caused share decline.
FDA review extended for denecimig due to manufacturing issues.
Bullish Signals
Novo Nordisk released real-world data demonstrating that oral Wegovy provides a meaningful alternative for patients avoiding injections, with users shedding an average of 4.1% body weight over three months.
A large retrospective study suggests escalating semaglutide doses lowers the risk of serious cardiovascular events by 6% compared to switching to tirzepatide, strengthening Novo Nordisk's position in the type 2 diabetes market.
Risk Factors
CFRA downgraded Novo Nordisk from hold to sell with a $38 price target, citing an unfavorable risk-reward profile and mounting competitive pressure.
Investors expressed skepticism regarding management's long-term growth targets, leading to a noticeable decline in shares following the capital markets day.
The FDA extended its review of denecimig due to corrective work needed at a manufacturing site, though this delay is not expected to impact 2026 financial guidance.
Novo Nordisk A/S faces an extension of the FDA review for its hemophilia treatment denecimig due to ongoing remediation work at a manufacturing facility. The US Food and Drug Administration has not established a new regulatory decision timeline, though Novo Nordisk aims for a US launch in the first half of 2027 pending approval. Crucially, the company stated that this regulatory delay does not alter its full-year 2026 financial outlook, framing the issue as operational rather than a revision to earnings forecasts.
Despite the regulatory headwind for denecimig, Novo Nordisk reported strong underlying performance in its second quarter of 2026. Adjusted sales rose 7 percent at constant exchange rates to DKK 78.488 billion, while adjusted operating profit increased by 11 percent to reach DKK 33.389 billion. These figures were released on August 4, 2026, and highlight a contrast between the specific regulatory hurdle for denecimig and the broader financial health of the company.
Looking ahead, Novo Nordisk will report its first three quarters of 2026 results on November 4, 2026. Investors will be watching to see if volume growth in its GLP-1 portfolio can offset pricing pressures and validate the company's full-year guidance range of 0 percent to minus 6 percent at constant exchange rates. This outlook represents an improvement from earlier estimates which ranged between minus 4 percent and minus 12 percent.
Novo Nordisk shares traded down 0.94 percent on October 5, 2026, closing at EUR 32.84 versus the prior close of EUR 33.15. The stock's market capitalization was valued at USD 165.7 billion as of October 2, 2026. While the denecimig review extension introduces uncertainty regarding that specific product launch, the company maintains its broader strategic trajectory and financial targets remain intact.
π FDA extended denecimig review due to facility remediation work.
π US launch of denecimig targeted for first half of 2027.
π Adjusted operating profit rose 11% to DKK 33.389 billion.
π― Full-year 2026 outlook improved to -6% to 0% growth.
π The FDA extended its review of Novo Nordisk's hemophilia treatment denecimig due to facility remediation work at a manufacturing site.
π Novo Nordisk aims for a US launch of denecimig in the first half of 2027, pending the completion of the regulatory review.
π The FDA feedback focused on facility remediation rather than clinical efficacy or safety data from the FRONTIER program.
π Novo Nordisk's stock price fell 0.94 percent to EUR 32.84 on October 5, 2026, trading below the prior close of EUR 33.15.
π° Second-quarter 2026 adjusted sales grew 7 percent at constant exchange rates to DKK 78.488 billion.
π Adjusted operating profit for Q2 2026 increased by 11 percent, reaching DKK 33.389 billion.
π― The company maintains its full-year 2026 adjusted sales and operating profit outlook range of 0 percent to minus 6 percent at constant exchange rates.
π This full-year guidance is an improvement from the earlier range of minus 4 percent to minus 12 percent.
ποΈ Novo Nordisk will announce financial results for the first three quarters of 2026 on November 4, 2026 at 7:30 a.m. CEST.
π Investors will assess whether GLP-1 volume growth can offset pricing pressure in the upcoming Q3 and Q4 reports.
Bullish Signals
Q2 2026 sales grew 7% to DKK 78.488 billion.
Adjusted operating profit surged 11% to DKK 33.389 billion.
Full-year outlook improved from -12% range to -6% max.
FDA delay is facility remediation, not efficacy or safety.
Risk Factors
FDA review delayed due to manufacturing remediation work.
Bullish Signals
Novo Nordisk reported strong second-quarter 2026 adjusted sales growth of 7 percent at constant exchange rates, reaching DKK 78.488 billion.
Adjusted operating profit for the second quarter of 2026 surged by 11 percent to DKK 33.389 billion, demonstrating robust underlying profitability.
The company improved its full-year 2026 adjusted sales and operating profit outlook range from minus 4 percent to minus 12 percent to a more optimistic 0 percent to minus 6 percent at constant exchange rates.
Novo Nordisk clarified that the FDA review extension for denecimig is an operational issue regarding facility remediation rather than a reflection of clinical efficacy or safety concerns.
Risk Factors
The FDA extended its review of denecimig due to ongoing remediation work at a manufacturing facility, delaying the regulatory decision timeline.
Novo Nordisk has not set a new regulatory decision timeline for denecimig, creating uncertainty regarding the US launch scheduled for the first half of 2027.
The company's full-year 2026 adjusted sales and operating profit outlook remains negative, with guidance capped at a maximum decline of 6 percent at constant exchange rates.
Novo Nordisk reported strong Q2 adjusted sales growth of 7 percent at constant exchange rates, reaching DKK 78.5 billion, driven by a 16 percent increase in obesity-care sales and 13 percent growth in international GLP-1 volumes. Despite this revenue expansion, the company's adjusted gross margin declined to 78.2 percent from 82.7 percent in the prior year quarter due to lower realized prices and increased manufacturing capacity costs.
Adjusted operating profit rose 11 percent to DKK 33.4 billion at constant exchange rates, though management maintains a flat-to-negative growth outlook for full-year 2026 ranging from 0% to -6%. The company faces a regulatory delay regarding its denecimig update in the U.S., with the FDA extending its review to address remediation work at a manufacturing facility. This regulatory action does not impact clinical efficacy or safety data and is expected to shift the potential U.S. launch timeline to the first half of 2027.
Strategically, Novo Nordisk agreed to acquire rights to HRS-1596, an experimental once-weekly obesity pill from Jiangsu Hengrui Pharmaceuticals, for up to USD 2.6 billion including a USD 300 million upfront payment. The company is preparing for its Q3 earnings release on November 3, 2026, where investors will assess the impact of pricing pressures and manufacturing execution against continued volume expansion in its core weight-loss portfolio.
π Novo Nordisk Q2 adjusted sales rose 7% to DKK 78.5 billion.
π° Adjusted operating profit grew 11% to DKK 33.4 billion.
π Obesity-care sales surged 16% while international GLP-1 sales grew 13%.
β οΈ FDA review of denecimig delayed U.S. launch to H1 2027 due to remediation.
π Novo Nordisk acquired HRS-1596 rights for up to USD 2.6 billion.
π Novo Nordisk Q2 adjusted sales grew 7 percent at constant exchange rates to reach DKK 78.5 billion.
π° Adjusted operating profit increased 11 percent to DKK 33.4 billion, though margins compressed to 78.2 percent.
π Obesity-care sales surged 16 percent in Q2 while international GLP-1 sales grew 13 percent.
β οΈ The FDA extended its review of denecimig due to manufacturing facility remediation work, delaying the U.S. launch to H1 2027.
π¬ Clinical efficacy and safety data for denecimig remain unaffected by the regulatory delay.
π Novo Nordisk acquired rights to HRS-1596 from Jiangsu Hengrui Pharmaceuticals for up to USD 2.6 billion.
π The company expects full-year 2026 adjusted sales growth of 0% to -6% at constant exchange rates.
ποΈ Q3 earnings are scheduled for release on November 3, 2026.
Bullish Signals
Q2 adjusted sales rose 7% to DKK 78.5B.
Obesity-care sales surged 16% in Q2.
International GLP-1 sales grew 13% in Q2.
Adjusted operating profit increased 11% to DKK 33.4B.
Secured HRS-1596 rights for up to USD 2.6B.
Risk Factors
FDA review delay pushes denecimig U.S. launch to H1 2027.
Adjusted gross margin fell to 78.2% from 82.7% due to costs.
Management forecasts flat-to-negative adjusted sales growth for 2026.
Bullish Signals
Novo Nordisk achieved a 7 percent increase in Q2 adjusted sales at constant exchange rates, reaching DKK 78.5 billion.
Obesity-care sales grew robustly by 16 percent in Q2, demonstrating strong demand for the company's core weight-loss portfolio.
International GLP-1 sales expanded by 13 percent in Q2, indicating successful volume growth outside domestic markets.
Adjusted operating profit rose 11 percent to DKK 33.4 billion despite margin compression from lower prices and capacity costs.
The company secured a strategic acquisition of HRS-1596 rights for up to USD 2.6 billion, diversifying its obesity treatment pipeline.
Risk Factors
The FDA extended the review period for denecimig due to remediation work at a manufacturing facility, delaying the U.S. launch to the first half of 2027.
Adjusted gross margin declined to 78.2 percent from 82.7 percent in the prior year quarter due to lower realized prices and manufacturing capacity costs.
Management forecasts flat-to-negative adjusted sales growth for full-year 2026, ranging from 0% to -6% at constant exchange rates.
Drug licensingLicensing agreementAI-generated analysis
Novo Nordisk (NVO) secured a significant licensing agreement with Chinese biotech firm Hengrui for the oral metabolic drug candidate HRS-1596. The deal grants Novo rights to develop and commercialize the once-weekly treatment outside of mainland China, Hong Kong, Macao, and Taiwan, with an upfront payment of $300 million and a total potential value up to $2.6 billion including future milestones and royalties.
HRS-1596 is designed as a dual-pathway inhibitor targeting GLP-1 and GIP receptors to address weight management and type 2 diabetes. The asset is currently ready for early human testing, with Hengrui holding clearance in China to initiate studies. The transaction remains subject to U.S. antitrust clearance and is expected to close in the fourth quarter.
This acquisition aligns with Novo Nordisk's strategic focus on expanding its obesity and diabetes pipeline through international partnerships. While the deal is narrower than Novartis' concurrent $7.8 billion RNA platform acquisition, it provides immediate access to a novel oral mechanism that complements Novo's existing injectable portfolio in key global markets.
π Novo Nordisk pays $300M upfront for exclusive HRS-1596 oral drug rights.
π° Deal value reaches up to $2.6B including milestones and royalties.
β³ Licensing pending U.S. antitrust clearance, projected Q4 closing.
π Novo develops HRS-1596 globally outside mainland China and Taiwan.
𧬠Novel oral alternative to Novo's injectable obesity and diabetes therapies.
π Novo Nordisk paid a $300 million upfront fee for exclusive rights to HRS-1596, an oral metabolic drug targeting GLP-1 and GIP pathways.
π° The total deal value could reach up to $2.6 billion when including development milestones and sales royalties in non-Chinese territories.
π¬ Hengrui has regulatory clearance in China to begin early-stage human testing of the once-weekly oral treatment for weight management and diabetes.
β³ The licensing agreement is pending U.S. antitrust clearance and is projected to close during the fourth quarter.
π Novo Nordisk will develop and commercialize HRS-1596 in all regions outside mainland China, Hong Kong, Macao, and Taiwan.
𧬠HRS-1596 represents a novel oral approach to obesity and diabetes, offering an alternative to Novo's current injectable therapies.
Bullish Signals
Acquired HRS-1596 rights for $300M upfront.
Expands pipeline with once-weekly oral GLP-1/GIP drug.
Deal value up to $2.6B on milestones.
Risk Factors
HRS-1596 deal faces U.S. antitrust clearance delay risk before Q4 close.
No commercial rights to HRS-1596 in China/HK/Macao/Taiwan, limiting global coverage.
Bullish Signals
Novo Nordisk acquired exclusive worldwide rights (excluding mainland China) to HRS-1596 for $300 million upfront, significantly expanding its oral metabolic disease pipeline.
The partnership with Hengrui provides immediate access to a once-weekly oral drug targeting both GLP-1 and GIP pathways, diversifying Novo's therapeutic approach beyond injections.
The deal includes substantial upside potential with total value reaching up to $2.6 billion contingent on successful development, regulatory approval, and commercial sales milestones.
Risk Factors
The HRS-1596 licensing agreement is subject to U.S. antitrust clearance, introducing a regulatory delay risk before the deal can close in the fourth quarter.
Novo Nordisk will not have commercial rights to HRS-1596 in mainland China, Hong Kong, Macao, or Taiwan, limiting its global market coverage for this specific asset.
CFRA has downgraded Novo Nordisk stock from Hold to Sell, setting a price target of USD 38.00. The analyst firm cites growing competition in the obesity medicine sector as a primary driver for this negative outlook, suggesting that market share pressures may limit future growth potential despite recent financial successes.
Financially, Novo Nordisk reported strong half-year performance with net sales reaching DKK 175.30 billion, representing an 18% increase at constant exchange rates compared to the previous year. Net income also surged to DKK 69.55 billion, driven by robust demand for its weight-loss and diabetes treatments.
However, a significant divergence exists between reported results and forward guidance. While second-quarter sales grew by 3%, the company's full-year adjusted sales growth guidance has been revised to a range of 0% to -6%. This contraction in outlook highlights intensifying pricing pressures and competitive dynamics that could dampen the stock's trajectory despite its strong historical performance.
The stock is currently trading around EUR 33.23, reflecting market skepticism regarding the sustainability of its high growth rates. With a market capitalization of approximately USD 166.1 billion, investors are closely watching how management navigates the transition from rapid expansion to a more mature, competitive landscape in the obesity drug market.
π CFRA downgraded NVO stock to Sell with a USD 38.00 price target citing obesity sector competition.
π° H1 net sales grew 18% to DKK 175.30 billion while Q2 sales rose 3% to DKK 78.50 billion.
π H1 net income surged to DKK 69.55 billion, significantly up from DKK 55.54 billion last year.
β οΈ Full-year adjusted sales growth guidance was revised down to a range of 0% to -6%.
ποΈ Q3 earnings results are scheduled for release on November 3, 2026.
π CFRA downgraded Novo Nordisk stock from Hold to Sell with a price target of USD 38.00 due to concerns over competition in the obesity medicine sector.
π° The company reported half-year net sales of DKK 175.30 billion, marking an 18% growth at constant exchange rates compared to the prior year.
π Net income for the first half of 2026 reached DKK 69.55 billion, up significantly from DKK 55.54 billion in the same period last year.
β οΈ Second-quarter sales grew by 3% to DKK 78.50 billion, but full-year adjusted sales growth guidance was revised to a range of 0% to -6%.
π The downgrade highlights growing tension between strong reported revenue and a deteriorating outlook for future organic growth.
π₯ Novo Nordisk faces increasing competitive pressure in the obesity drug market, which analysts believe could constrain pricing power and margins.
π The stock traded at EUR 33.23 on October 2, 2026, showing minimal movement despite the negative analyst action.
ποΈ The company is scheduled to release its third-quarter earnings results on November 3, 2026, providing further clarity on its growth trajectory.
Bullish Signals
Net sales reached DKK 175.30B, up 18% in H1 2026.
Net income jumped to DKK 69.55B in H1 2026.
Risk Factors
CFRA downgraded to Sell with $38.00 target due to competition.
Full-year sales guidance revised to 0% to -6% contraction.
Q2 sales growth slowed to 3% amid saturation.
Bullish Signals
Novo Nordisk generated DKK 175.30 billion in net sales for the first half of 2026, representing an 18% increase at constant exchange rates.
The company reported a significant jump in net income to DKK 69.55 billion during the first half of 2026 compared to DKK 55.54 billion a year earlier.
Risk Factors
CFRA downgraded Novo Nordisk from Hold to Sell with a price target of USD 38.00, citing intensifying competition in the obesity medicine sector.
Full-year adjusted sales growth guidance was revised to a range of 0% to -6%, indicating expected contraction despite recent quarterly gains.
Second-quarter sales growth of only 3% suggests that the rapid expansion phase may be slowing as market saturation and pricing pressures mount.
Novo Nordisk A/S is exploring a strategic shift to open its New York listing, potentially replacing American depositary receipts with direct shares to enhance its U.S. market profile. This move was discussed by CEO Mike Doustdar, though no final decision has been announced as of early October 2026.
Financial performance for the second quarter of 2026 showed adjusted sales rising 7% to DKK 78.49 billion, driven by a 16% surge in obesity care sales and an 11% increase in operating profit. However, U.S. operations grew more modestly at 4%, reflecting mixed regional dynamics.
Despite strong quarterly results, the company's full-year 2026 outlook remains cautious, projecting adjusted sales growth between 0% and a decline of up to 6% due to pricing pressures and intensifying competition. The stock fell 1.10% on October 1, 2026, as investors weighed these factors alongside upcoming Q3 earnings.
Analyst sentiment is divided, with Jefferies cutting its price target to DKK 275 and reducing its valuation multiple amid concerns over patent expiry for semaglutide. Investors will watch the November 3, 2026 earnings release to determine if recent sales growth can sustain momentum through the year.
π Novo Nordisk stock fell 1.10% to EUR 33.20 on October 1, 2026.
π Q2 adjusted sales rose 7% year-over-year with obesity care up 16%.
π° Adjusted operating profit increased 11% in the second quarter of 2026.
β οΈ Full-year 2026 outlook forecasts adjusted sales growth between 0% and -6%.
Novo Nordisk (NVO) is currently trading at a discount relative to sector earnings multiples, yet it appears expensive when evaluated on a free cash flow basis due to elevated capital expenditure requirements. The article highlights that the market has priced in a scenario where Novo's capex remains high, effectively doubting management's guidance to normalize these spending levels by 2030.
Management's ability to reduce capital expenditure is identified as a pivotal factor for unlocking significant shareholder value. If successful, free cash flow could rise from approximately DKK 50 billion to DKK 125 billion. However, the current stock valuation suggests investors are skeptical that these savings will be returned to shareholders rather than being diverted toward acquisitions.
Beyond capital allocation concerns, the company faces specific external risks including pricing pressure in the United States and potential losses on international loaned-out entities (LOE). The author argues that the market had already formed a negative opinion regarding Novo Nordisk before its recent Capital Markets Day event concluded.
π Novo Nordisk trades at sector earnings discount but expensive on free cash flow.
ποΈ Management guides to normalize capital expenditure by 2030 for financial trajectory.
π° Capex normalization could unlock value, raising free cash flow from DKK 50B to DKK 125B.
β οΈ Risks include US pricing pressure and potential losses on international loaned-out entities.
π Savings may be diverted to acquisitions instead of shareholder returns.
π Novo Nordisk trades at a discount to sector earnings multiples but appears expensive on a free cash flow basis due to elevated capital expenditure.
ποΈ Management has provided guidance to normalize capital expenditure by 2030, which is viewed as pivotal for the company's financial trajectory.
π° Successful capex normalization could unlock significant shareholder value by raising free cash flow from DKK 50B to DKK 125B.
π Current stock pricing reflects a market scenario where capital expenditure remains elevated rather than decreasing as promised.
β οΈ Key risks facing the company include ongoing US pricing pressure and potential losses on international loaned-out entities (LOE).
π There is a risk that any capex savings achieved by management may be diverted to acquisitions instead of being returned to shareholders.
Risk Factors
Stock expensive due to elevated capital expenditure levels.
Novo Nordisk (NVO) has experienced a significant share price decline of over 70% from its recent highs, driven primarily by intensifying competition in the GLP-1 drug market. Despite this volatility, the company is viewed as a compelling long-term investment opportunity due to its diversified portfolio, robust research and development pipeline, and recent milestones achieved in rare disease treatments.
The company has provided improved guidance for 2026, supported by strong international sales momentum. Financially, Novo Nordisk expects its free cash flow yield to rise as capital expenditures normalize, with specific guidance set for $7.6 billion in free cash flow and a dividend yield of 4.6%.
While competition remains a key risk factor, the article highlights that Novo Nordisk's continued innovation and strategic capital allocation underpin a positive long-term outlook. The investment thesis relies on the company's ability to maintain its market position through product differentiation and operational efficiency despite the challenging competitive landscape.
π Stock dropped >70% due to increased GLP-1 sector competition.
π Issued improved 2026 guidance driven by strong international sales.
π° Free cash flow expected to rise with $7.6B capex guidance.
π¦ Offers attractive 4.6% dividend yield for investors.
π Novo Nordisk's share price has dropped more than 70% from recent highs due to increased competition in the GLP-1 drug sector.
π The company maintains a robust R&D pipeline and has achieved significant milestones in rare disease treatments.
π Novo Nordisk has issued improved guidance for 2026, driven by strong international sales momentum.
π° Free cash flow is expected to rise as capital expenditures normalize, with guidance set at $7.6 billion.
π¦ The company offers a 4.6% dividend yield, providing attractive income potential for investors.
β οΈ Intensifying competition in the GLP-1 market is identified as a primary risk to the stock's performance.
Bullish Signals
Compelling investment despite 70% decline with robust R&D pipeline.
Risk Factors
Competition in GLP-1 segment caused 70% share price drop.
Valuation compressed after GLP-1 drug pricing peaks.
Bullish Signals
Novo Nordisk remains a compelling long-term investment despite a 70% share price decline, supported by its diversified portfolio and robust R&D pipeline.
The company has achieved rare disease milestones that support improved 2026 guidance and demonstrate continued innovation beyond GLP-1s.
International sales momentum is driving revenue growth, helping to offset headwinds from domestic competition.
Free cash flow yield is set to rise as capex normalizes, with specific guidance for $7.6 billion in FCF for 2026.
The company offers a 4.6% dividend yield, providing strong income characteristics alongside capital appreciation potential.
Risk Factors
Intensifying competition, particularly in the GLP-1 segment, is identified as a key risk that has already contributed to a 70% drop in share price.
The stock has suffered significant valuation compression following the initial excitement and peak pricing of its GLP-1 drugs.
Company updateGuidance raisedPatent expiryAI-generated analysis
Novo Nordisk (NYSE:NVO) faces renewed investor scrutiny following a share-price decline of over 70% from its peak, driven by concerns that its core weight-loss franchise may lose ground to competitors. Despite these challenges, the company raised its 2026 sales and operating-profit growth guidance to a range of 0% to negative 6% at constant exchange rates, an improvement from the prior outlook of negative 4% to negative 12%. This upward revision suggests management believes current operations have stabilized more than previously expected, providing some room to fund pipeline development.
The company is actively pursuing a 'second act' strategy to mitigate risks associated with patent expiries and generic competition. CEO Mike Doustdar has implemented cost-cutting measures, ended weak programs, and focused on targeted acquisitions. Novo possesses five oral drug candidates in development, aiming for them to capture up to half of the obesity market by 2030, leveraging delivery-technology patents extending into the mid-to-late 2030s to differentiate its franchise beyond the injectable patent cycle.
However, significant headwinds remain. Analysts project Eli Lilly's Zepbound will outsell Novo's Wegovy by more than $7 billion this year, and Novo recently halted trials for heart drug ziltivekimab after CagriSema disappointed investors. Generic semaglutide competition has already begun in markets like India, Canada, and Brazil, exposing the company to price erosion before the major Western patent cliff in the early 2030s. While hedge fund interest in NVO has increased, the widening lead of its rival and recent pipeline setbacks make diversification urgent.
π Shares lost over 70% from peak amid weight-loss franchise doubts.
π Raised 2026 guidance to 0% to negative 6% growth range.
π Five oral candidates aim to capture half obesity market by 2030.
β οΈ Eli Lilly Zepbound projected to outsell Wegovy by $7 billion this year.
π¬ Halted heart drug trials after CagriSema disappointment left pipeline sparse.
π Novo Nordisk (NVO) shares have lost more than 70% of their value from the peak, inviting hard questions about the future of its weight-loss franchise.
π The company raised its 2026 sales and operating-profit growth guidance to a range of 0% to negative 6%, an improvement from the prior outlook of negative 4% to negative 12%.
π Novo Nordisk has five oral drug candidates in development, with expectations that pills could capture as much as half of the obesity market by 2030.
β οΈ Analysts project Eli Lilly's Zepbound will outsell Novo's Wegovy by more than $7 billion this year, intensifying competitive pressure.
π¬ The company halted trials for heart drug ziltivekimab after CagriSema disappointed investors, leaving the late-stage pipeline described as sparse.
π Generic semaglutide competition has entered markets including India, Canada, and Brazil following 2026 patent expiries, exposing the brand to price erosion.
π Hedge fund count for NVO rose to 59 in Q2 2026 with position value climbing to $2.00 billion, though still trailing rival Eli Lilly significantly.
π‘οΈ Novo holds delivery-technology patents extending into the mid-to-late 2030s to differentiate its franchise beyond the injectable patent cycle.
π’ CEO Mike Doustdar has cut costs, ended weak programs, and pursued targeted acquisitions to build a credible second act.
π Every point of market share Novo loses carries a large opportunity cost as the obesity market potentially exceeds $100 billion by the early 2030s.
Bullish Signals
Raised 2026 guidance to 0% to -6% growth.
Five oral drugs could capture half obesity market by 2030.
Delivery patents extend into mid-to-late 2030s.
Hedge fund positions rose to $2.00 billion in Q2.
Risk Factors
Shares down >70% from peak due to franchise skepticism.
Lilly's Zepbound projected to outsell Wegovy by >$7B.
Halted heart drug trials after CagriSema disappointment.
Generic competition post-2026 exposes brand to price erosion.
Market share loss costly in >$100B obesity market.
Bullish Signals
Novo Nordisk raised its 2026 sales and operating-profit growth guidance to a range of 0% to negative 6%, an improvement from the prior outlook of negative 4% to negative 12%.
The company possesses five oral drug candidates in development, with expectations that pills could capture as much as half of the obesity market by 2030.
Novo holds delivery-technology patents extending into the mid-to-late 2030s to differentiate its franchise beyond the injectable patent cycle.
Hedge fund count for NVO rose to 59 in Q2 2026 with position value climbing to $2.00 billion, indicating renewed institutional interest.
Risk Factors
Novo Nordisk shares have lost more than 70% of their value from the peak, reflecting significant investor skepticism about the future of its weight-loss franchise.
Analysts project Eli Lilly's Zepbound will outsell Novo's Wegovy by more than $7 billion this year, intensifying competitive pressure on market share.
The company halted trials for heart drug ziltivekimab after CagriSema disappointed investors, leaving the late-stage pipeline described as sparse.
Generic semaglutide competition has entered markets including India, Canada, and Brazil following 2026 patent expiries, exposing the brand to price erosion.
Every point of market share Novo loses carries a large opportunity cost as the obesity market potentially exceeds $100 billion by the early 2030s.
Novo Nordisk has signed a worldwide licensing and collaboration agreement with Swedish drug delivery specialist Nanexa, centered on the PharmaShell technology. The deal could be worth up to EUR 1.165 billion to Nanexa, including EUR 615 million in upfront payments and milestone fees. Under this arrangement, Novo Nordisk secures exclusive rights to deploy the technology across up to five development programmes focused on long-acting injectables for obesity, type 2 diabetes, and other cardiometabolic conditions.
The company is simultaneously advancing its CagriSema pipeline, with recent Phase 3 data showing an estimated average weight loss of 12.4% in adults with type 2 diabetes after roughly 60 weeks, compared to 9.1% for Eli Lilly's tirzepatide. At a 1.0 milligram dose, CagriSema delivered a 21% reduction in weight versus placebo and proved superior to higher doses of tirzepatide in the diabetes study. Novo Nordisk plans to align the regulatory pathway for the type 2 diabetes indication with health authorities.
Despite these strategic moves, investor sentiment remains cautious due to competitive pressures and valuation concerns. CFRA recently downgraded Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target, citing that annual revenue growth of 3.6% is already priced into the stock. The company faces challenges in defending its therapeutic edge against rivals like Eli Lilly while managing patent expirations and maintaining operating margins amidst fierce competition in the obesity therapy market.
π€ Novo Nordisk secures EUR 1.165B Nanexa deal for PharmaShell tech across five programs.
π° Agreement includes EUR 615M in upfront and milestone payments to partner.
π CagriSema shows 12.4% weight loss, outperforming Eli Lilly's tirzepatide at 9.1%.
π CFRA downgrades stock to Sell with USD 38 price target due to valuation.
π¬ Partners with Anthropic AI to compress study report production from months to minutes.
π€ Novo Nordisk signs a EUR 1.165 billion licensing deal with Nanexa for exclusive rights to deploy PharmaShell technology across up to five development programmes.
π° The agreement includes EUR 615 million in upfront, development, and regulatory milestone payments to the Swedish partner.
π CagriSema Phase 3 data shows a 12.4% average weight loss in type 2 diabetes patients, outperforming Eli Lilly's tirzepatide at 9.1%.
βοΈ At a 1.0 milligram dose, CagriSema achieved a 21% weight reduction versus placebo and was superior to 5 mg of tirzepatide in the diabetes study.
π CFRA downgrades Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target due to valuation concerns.
π Shares finished Friday at EUR 34.05, up 0.2%, but are down 23% year-to-date and 38% below the 52-week high.
π― Novo Nordisk aims for risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035 with more than five multi-blockbuster products by 2030.
π¬ The company partners with Anthropic to use Claude AI models, compressing study report production from months to minutes.
ποΈ From 28 September to 2 October, Novo Nordisk will present 44 pieces of research on semaglutide, CagriSema, and zenagamtid at the EASD meeting in Milan.
β οΈ Management concedes that 2030 targets carry uncertainties and do not constitute a binding financial forecast.
Bullish Signals
Secures exclusive rights for Nanexa PharmaShell across five obesity/diabetes programmes.
Deal valued up to EUR 1.165B with EUR 615M upfront.
Risk Factors
CFRA downgrades stock to Sell with $38 price target.
Shares down 23% YTD, 38% below 52-week high.
Bullish Signals
Novo Nordisk secures exclusive rights to deploy Nanexa's PharmaShell technology across up to five development programmes for obesity and type 2 diabetes.
The deal with Nanexa is valued at up to EUR 1.165 billion, including EUR 615 million in upfront and milestone payments.
Risk Factors
CFRA downgrades Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target.
Shares are down 23% year-to-date and sit 38% below their 52-week high amid fierce competitive intensity.
Novo Nordisk (NVO) has entered into an exclusive global licensing agreement with Nanexa to acquire PharmaShell coating technology. This platform is designed for long-acting peptide injectables targeting obesity, type 2 diabetes, and other cardiometabolic conditions, aiming to enable monthly or quarterly dosing schedules.
Under the terms of the deal, Nanoexa can earn up to β¬1.165 billion (approximately $1.33 billion) in total value. This includes β¬615 million in upfront payments alongside development and regulatory milestones, plus low single-digit royalties. Novo Nordisk will retain full responsibility for the development and commercialization of these programs.
The agreement covers up to five distinct programs and represents a strategic shift toward acquiring delivery engines rather than just late-stage assets. This move aligns with broader industry trends where major pharmaceutical companies are paying premiums for platforms that enhance their existing portfolios in high-growth areas like obesity and diabetes.
π€ Novo Nordisk exclusively licenses Nanexa PharmaShell for obesity and diabetes injectables.
π° Deal includes β¬615M upfront plus up to β¬1.165B in milestones for Nanoexa.
π Partnership enables monthly or quarterly dosing frequencies for Novo's cardiometabolic programs.
π Novo Nordisk licensed Nanexa's PharmaShell coating technology exclusively for long-acting peptide injectables in obesity and type 2 diabetes.
π° The deal allows Nanoexa to earn up to β¬1.165 billion, including β¬615 million in upfront payments and development milestones.
π¬ The partnership targets monthly or quarterly dosing frequencies for Novo's cardiometabolic programs.
π€ Novo Nordisk will manage all future development and sales activities for the licensed technology.
π Retail sentiment around NVO was extremely bullish despite a 24% year-to-date stock decline.
π This acquisition supports Novo's strategy of buying delivery platforms rather than single late-stage assets.
Bullish Signals
Secured exclusive global license for PharmaShell coating technology.
Deal includes β¬615M upfront plus up to β¬1.165B milestones.
Partnership enables monthly/quarterly dosing for better adherence.
Risk Factors
Stock declined 24% year-to-date.
Retail sentiment is extremely bullish.
Bullish Signals
Novo Nordisk secured an exclusive global license for PharmaShell coating technology to enable long-acting peptide injectables for obesity and diabetes.
The deal includes substantial upfront payments of β¬615 million (approx. $700M) plus up to β¬1.165 billion in total value including milestones.
The partnership aims to achieve monthly or quarterly dosing, potentially improving patient adherence and quality of life for cardiometabolic patients.
Risk Factors
Novo Nordisk's stock has declined 24% year-to-date, contrasting with Eli Lilly's 10% gain during the same period.
Retail sentiment on StockTwits was extremely bullish while broader market sentiment for competitors like AbbVie and Novartis was bearish.
Drug approvalLicensing agreementNew drug indicationAI-generated analysis
Novo Nordisk shares fell 10% over seven days, closing at EUR 33.94, as investors reacted negatively to a 2026-2030 revenue target that aligned with industry averages. Despite recent regulatory wins for FREHEMGO and Sogroya in Europe, the market remains fixated on the looming patent expiry of its blockbuster semaglutide franchise, viewing the company's ambition as insufficient to offset future volume declines.
The Danish drugmaker recently secured a worldwide exclusive license to Nanexa's PharmaShell technology for up to EUR 1.165 billion in potential payments, aiming to extend dosing intervals and differentiate its obesity treatments. Concurrently, Singapore approved Wegovy for treating non-cirrhotic MASH, expanding the drug's indications beyond weight management.
Clinically, Novo Nordisk demonstrated strong pipeline momentum with CagriSema achieving 12.4% weight loss in the REIMAGINE 5 trial and 21.0% in the REDEFINE 9 study, outperforming rivals. However, analysts warn that converting this pipeline into durable earnings is challenging due to potential price erosion on GLP-1s and regulatory risks surrounding the FDA's review of CagriSema for weight management.
Management plans to expand oral formulation capacity tenfold but faces structural headwinds including muted medium-term growth expectations and the risk of margin pressure if production expansion lags behind price cuts. The company has repurchased B-shares worth over DKK 9.6 billion since February, yet the stock remains down 23% year-to-date as investors question its ability to maintain pricing power post-2030.
π Shares dropped 10% after revenue targets matched industry averages, failing to reassure investors about patent expiry risks.
π EMA recommended FREHEMGO and Sogroya approval to diversify the portfolio beyond the GLP-1 franchise.
π CagriSema Phase 3 trials showed superior efficacy with 21.0% weight loss compared to placebo and tirzepatide.
π€ Secured exclusive Nanexa license for up to EUR 1.165 billion to extend dosing intervals for obesity treatments.
β οΈ Analysts flagged structural headwinds including muted growth and looming semaglutide exclusivity loss after 2030.
π Novo Nordisk shares dropped 10% over seven days after management presented a 2026-2030 revenue target that matched industry averages, failing to reassure investors about the company's ability to offset semaglutide patent expiry.
π The European Medicines Agency recommended approval for FREHEMGO and Sogroya, marking significant regulatory wins intended to diversify the portfolio beyond the GLP-1 franchise.
π CagriSema Phase 3 trials showed superior efficacy with 21.0% weight loss in the REDEFINE 9 study compared to placebo, while outperforming tirzepatide in the REIMAGINE 5 trial.
π€ Novo Nordisk secured a worldwide exclusive license to Nanexa's PharmaShell technology for up to EUR 1.165 billion in payments to extend dosing intervals for obesity treatments.
πΈπ¬ Singapore's regulator approved Wegovy as the first therapy for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis, expanding the drug's therapeutic indications.
β οΈ Analysts flagged structural headwinds including muted medium-term growth and the looming loss of semaglutide exclusivity after 2030 as key risks to the company's valuation.
π The stock is down 23% year-to-date, with investors concerned that pricing power in the core business may be eroding faster than production capacity can expand.
π Management signaled plans to expand oral formulation capacity enough to treat ten times as many people with obesity, contingent on maintaining healthy margins.
π A US FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026, adding a critical regulatory milestone to the company's near-term catalysts.
π° Novo Nordisk has repurchased B-shares worth more than DKK 9.6 billion since February as a partial offset to recent stock weakness and investor skepticism.
Bullish Signals
EMA recommended FREHEMGO for hemophilia A, launching Q4 2026.
CagriSema FDA review carries regulatory delay/safety risks.
Ascendis Pharma rights return highlights partnership risks.
Stock down 23% YTD on growth ambition skepticism.
Bullish Signals
The European Medicines Agency recommended approval for FREHEMGO for hemophilia A treatment, with a planned European launch in the fourth quarter of 2026.
Sogroya received a positive opinion from the EMA for treating children with idiopathic short stature, positioning it as the first authorized therapy for this indication in the EU.
CagriSema achieved 12.4% weight loss after 60 weeks in the REIMAGINE 5 trial, outpacing tirzepatide's 9.1% and proving non-inferior on HbA1c reduction.
The REDEFINE 9 obesity study demonstrated CagriSema achieving 21.0% weight loss after 68 weeks compared to just 2.0% for placebo.
Singapore's regulator approved Wegovy as the first therapy for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis.
Novo Nordisk secured a worldwide exclusive license to Nanexa's PharmaShell technology, carrying upfront and milestone payments of up to EUR 1.165 billion.
The company plans to expand oral formulation capacity enough to treat ten times as many people with obesity if margins hold.
Risk Factors
Novo Nordisk shares dropped 10% over seven days as the market reacted negatively to a 2026-2030 revenue target that landed squarely in line with industry averages.
Analysts flagged muted medium-term growth and the looming loss of semaglutide exclusivity after 2030 as structural headwinds threatening long-term value.
Investors expressed concern during a capital markets day regarding pricing power erosion and whether acquisition strategy can offset post-semaglutide volume declines.
The bear scenario involves GLP-1 price erosion accelerating faster than production capacity expands, which would put sustained pressure on margins.
CagriSema remains under FDA review for weight management, carrying regulatory risk that delays or safety signals could deal a serious blow to medium-term growth targets.
The return of rights to TransCon technologies to Ascendis Pharma highlights risks associated with external partnerships and commercialization engines.
Year-to-date, the stock is down 23 percent, reflecting significant investor skepticism about the company's ability to deliver on growth ambitions without drastic margin erosion.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)